Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05364021 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
A Phase 1 study of Dravet Syndrome and Lennox Gastaut Syndrome, sponsored by Longboard Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT05364021 is a Phase 1 study of Dravet Syndrome and Lennox Gastaut Syndrome that has completed, run by Longboard Pharmaceuticals. The registered enrollment target is 52 participants, below the 106-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05364021, a Phase 1 study of Dravet Syndrome and Lennox Gastaut Syndrome, has completed, sponsored by Longboard Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LP352
Study Locations (20)
Florida
- Northwest Florida Clinical Research Group - Gulf Breeze
- University of Miami - Miami
- Advent Health Orlando - Orlando
- Research Institute of Orlando - Orlando
- University of South Florida - Tampa
California
- Rancho Los Amigos National Rehabilitation Center (RLANRC) - Downey
- Children's Hospital of Orange County - Orange
- University of California San Francisco - San Francisco
New York
- Boston Children's Health Physicians LLP - Hawthorne
- New York University Langone Hospital - Long Island - Mineola
- Northwell Health - New York
Arizona
- University of Arizona - Health Sciences Center - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Idaho
- Consultants in Epilepsy and Neurology - Boise
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05364021
The ClinicalTrials.gov registry entry for NCT05364021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (51% lower). The listed sponsor is Longboard Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Dravet Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05364021 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT05364021 about?
NCT05364021 is a clinical study titled "Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies". The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
What is the current status of trial NCT05364021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2022-03-03. Estimated completion is 2023-11-20.
What conditions does trial NCT05364021 study?
This clinical trial studies the following conditions: Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathy.
What interventions are being tested in trial NCT05364021?
The interventions under investigation include: Placebo (DRUG), LP352 (DRUG).
Who is sponsoring clinical trial NCT05364021?
This trial is sponsored by Longboard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05364021 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
COMPLETED · Phase 1
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RECRUITING · Phase 3
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
-
GABA Biomarkers in Dravet Syndrome
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.